SSA
MIRM icon

Schonfeld Strategic Advisors’s Mirum Pharmaceuticals MIRM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,317
Closed -$536K – 2373
2025
Q3 		$536K Buy
+7,317
New +$465K ﹤0.01% 1658
2025
Q2 		– Sell
-18,425
Closed -$830K – 2346
2025
Q1 		$830K Buy
18,425
+1,225
+7% +$57.7K 0.01% 1362
2024
Q4 		$711K Buy
17,200
+487
+3% +$20.3K ﹤0.01% 1265
2024
Q3 		$652K Sell
16,713
-5,531
-25% -$221K ﹤0.01% 1319
2024
Q2 		$761K Buy
+22,244
New +$583K ﹤0.01% 1321
2023
Q4 		– Sell
-21,799
Closed -$689K – 2079
2023
Q3 		$689K Sell
21,799
-15,966
-42% -$437K 0.01% 1131
2023
Q2 		$977K Sell
37,765
-57,660
-60% -$1.53M 0.01% 984
2023
Q1 		$2.29M Buy
95,425
+45,623
+92% +$1.04M 0.02% 653
2022
Q4 		$971K Buy
49,802
+5,262
+12% +$104K 0.01% 1164
2022
Q3 		$936K Buy
+44,540
New +$1.07M 0.01% 1316

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Schonfeld Strategic Advisors's MIRM Position: Q4 2025 in Review

Schonfeld Strategic Advisors sold out of Mirum Pharmaceuticals (MIRM) in Q4 2025, closing a stake of 7,317 shares — an estimated $536K sold.

Schonfeld Strategic Advisors first reported a position in MIRM in Q3 2022 and held it in 10 quarters. The position peaked at $2.29M in Q1 2023. 281 funds tracked by Wall St. Rank hold MIRM as of Q4 2025.

  • Schonfeld Strategic Advisors reported no remaining Mirum Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 7,317 Mirum Pharmaceuticals shares in Q4 2025, an estimated $536K.
  • Schonfeld Strategic Advisors first reported a position in Mirum Pharmaceuticals in Q3 2022 and held it in 10 quarters.
  • Schonfeld Strategic Advisors's Mirum Pharmaceuticals position peaked at $2.29M in Q1 2023.
  • 281 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q4 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.